Fairvalue-Calculator Fairvalue-Calculator
EN DE

BioNeutra Global Corporation (BGACF) Fair Value & Analysis

Consumer Defensive · US · Market cap $260K

Price$0.0056
Fair Value$0.0058
Upside+4.4%
Quality89/100
Evidence: Low Range $0.0058 – $0.0075

Fair value as of: Jun 26, 2026

Analysis

BioNeutra Global Corporation (BGACF) currently trades at $0.0056, while our model-based Fair Value estimate is $0.0058 — implying the stock looks roughly 4.4% undervalued today. We read business quality at 89/100 (high quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

BioNeutra Global Corporation engages in the research and development, production, and commercialization of food for nutraceutical, functional, and mainstream food and beverage products with a focus on oligosaccharides. The company offers isomalt oligosaccharide ingredients under the VitaFiber brand for human digestive health. It operates in Canada, the United States, Australia, New Zealand, European Union, and the Asia Pacific. The company is headquartered in Vancouver, Canada.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is BioNeutra Global Corporation (BGACF) undervalued?
As of Jun 26, 2026, our model estimates a fair value of $0.0058 versus a price of $0.0056 — about +4% (undervalued). Model-based estimate, not financial advice.
What is the fair value of BGACF?
Our 21-model fair value for BioNeutra Global Corporation is $0.0058 (as of Jun 26, 2026), built from audited fundamentals. The current price is $0.0056.
What is the quality score of BGACF?
BioNeutra Global Corporation has a Quality Score of 89/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.